Abcam, ab100522, Human Fractalkine ELISA Kit (CX3CL1)

Size: 1 x 96Tests
Human Fractalkine ELISA Kit (CX3CL1) is a Sandwich (quantitative) ELISA for the measurement of Human Fractalkine (CX3CL1) in Human in Biofluids, Cell Culture Media samples.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Cell culture supernatant,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:< 300 pg/mL,
Range:0.25 - 60 ng/mL,
Assay Platform:Microplate

Product details:
Abcam's CX3CL1 (Fraktaline) Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an
in vitro
enzyme-linked immunosorbent assay for the quantitative measurement of Human CX3CL1 in plasma and cell culture supernatants. (Human CX3CL1 concentration is pretty low in normal plasma, it may not be detected in this assay).
This assay employs an antibody specific for human CX3CL1 coated on a 96-well plate. Standards and samples are pipetted into the wells and CX3CL1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human CX3CL1 antibody is added. After washing away unbound biotinylated antibody, HRPconjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of CX3CL1 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
We have not been able to detect endogenous Human Fractalkine in normal serum with ab100522, only in serum spiked with Human Fractalkine.
Get higher sensitivity in only 90 minutes with Human Fractalkine ELISA Kit (CX3Cl1) (
ab192145
) from our SimpleStep ELISA
range.
Optimization may be required with urine samples

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CX3CL1 also known as fractalkine is a chemokine protein characterized mechanically by its dual function as both a chemoattractant and adhesion molecule. It exhibits a unique membrane-bound structure and can exist in a soluble form after proteolytic cleavage. The mass of CX3CL1 is approximately 42-45 kDa. This protein is highly expressed in endothelial cells neurons and tissues with substantial vascularization. Considerable interest surrounds the potential of CX3CL1 assessment in various studies often involving applications like fractalkine ELISA or assays on mouse models.
Biological function summary
CX3CL1 is involved in the immune system and nervous system functions influencing leukocyte adhesion and migration. It is not known to be part of a large multiprotein complex but directly interacts with its fractalkine receptor CX3CR1 on the surface of immune cells. This interaction regulates communication between neurons and microglia which highlights its role in neuroinflammation. CX3CL1's expression and function suggest a significant influence over inflammatory responses and homeostatic balance within these systems.
Pathways
CX3CL1 plays a role in the MAPK and PI3K-Akt pathways vital for cell survival proliferation and migration. Within these pathways CX3CL1 influences and interacts with several proteins thereby modulating inflammatory responses and cellular migration. These pathways are essential for immune system regulation where CX3CL1 acts as a mediator in signal transduction processes that connect immune responses to cellular activities such as proliferation and survival.
CX3CL1 has associations with neurodegenerative disorders like Alzheimer's disease and inflammatory diseases such as rheumatoid arthritis. Alterations in CX3CL1 expression or its fractalkine receptor function can influence disease progression by affecting how immune cells communicate and migrate to inflamed or damaged tissues. CX3CR1 the receptor for CX3CL1 represents an important link in these connections driving research efforts to explore therapies targeting these interactions to alleviate disease symptoms.